April 16, 2025 – Talk Bio

Trump pledges his support for a change to the IRA long sought by drugmakers

1 week ago talkbio0Tagged Biological Factors, Contraceptives, Oral, drug price, drugmakers, Industry, IRA, Mediation, Medicare, Prices

IRA, Medicare, Contraceptives, Oral, Mediation, Industry, drug price, Biological Factors, Prices, drugmakers, Medicare

Ayrmid misses deadline for detailed offer to top private equity bid for bluebird

1 week ago talkbio0Tagged Ayrmid, Capital, deadline, Failed, Family Turdidae (organism), gene therapy, Private Equity, proposal - intent, United States Food and Drug Administration

Ayrmid, Family Turdidae (organism), gene therapy, Failed, Capital, proposal – intent, United States Food and Drug Administration, private equity, deadline

Glycomine raises $115M to see if it can treat rare glycosylation disorder

1 week ago talkbio0Tagged Congenital disorder of glycosylation type 1A, GLM101, Glycomine, Infrequent

Infrequent, GLM101, Glycomine, Congenital disorder of glycosylation type 1A

U.S. Biotechs Reveal Tariff Exposure as Trade Inquiry Signals Imminent Pharmaceutical Tariffs

1 week ago talkbio0Tagged Evaluation, global supply chain, Impact food supplement, Import, Manufacturing, pharmaceutical ingredients, pharmaceutical tariffs, Policy, regulatory, reshoring, Sectioning technique, supply chain exposure, TNFRSF19 gene, United States

U.S. biotech, pharmaceutical tariffs, Section 232 investigation, supply chain exposure, trade policy, import costs, reshoring manufacturing, drug pricing, global supply chain, pharmaceutical ingredients, regulatory impact

CDC advisors broaden RSV vaccine recommendations to at-risk adults in their 50s

1 week ago talkbio0Tagged 50–59, Adult, Age, Arexvy, broaden, Centers for Disease Control and Prevention (U.S.), Chronic Condition, Recommendation, Respiratory syncytial virus, Severe (severity modifier), Vaccines

Adult, Respiratory syncytial virus, Centers for Disease Control and Prevention (U.S.), Vaccines, Recommendation, Age, Arexvy, Chronic Condition, Severe (severity modifier), 50–59, broaden

Pharma’s wins and losses in Trump’s sprawling executive order on drug prices

1 week ago talkbio0Tagged drug price, Industry, Insulin, IRA, losses, Mediation, Medicare, Prices, small molecule drugs

Medicare, Medicare, Industry, drug price, Mediation, small molecule drugs, losses, IRA, Insulin, Prices

Novartis Halts Phase 2 Osteoarthritis Study of ADAMTS-5 Inhibitor Due to Lack of Pain Relief

1 week ago talkbio0Tagged ADAMTS-5, cartilage degradation, Clinical Trial Termination, Degenerative polyarthritis, Drug Development, Inhibitor, Knee pain, M6495, Novartis, Pain, QUC398

Novartis, phase 2 trial, osteoarthritis, knee pain, ADAMTS-5 inhibitor, QUC398, M6495, clinical trial termination, pain relief, cartilage degradation, drug development

Sanofis $1.4B Kymab Bet Falters as Asthma Drug Stumbles in Phase II

1 week ago talkbio0Tagged Amlitelimab, Asthma, Immunology, Kymab, sanofi

Asthma, Amlitelimab, Kymab, sanofi, Immunology

Navigating the Biotech Winter: Strategies for Survival and Growth Amid Ongoing Industry Downturn

1 week ago talkbio0Tagged Acquisitions, adaptation, Artificial Intelligence, biotech downturn, growth opportunities, innovation, Landscapes, layoff, Precision Medicine, regulatory, strategic, Survival, trends qualifier

biotech downturn, layoff trends, funding challenges, strategic adaptation, innovation, mergers & acquisitions, workforce planning, precision medicine, artificial intelligence, regulatory landscape, survival strategies, growth opportunities

Sanofi backs $90M financing for I&I biologic developer

1 week ago talkbio0Tagged financing characteristics, I&I, sanofi, Series

sanofi, Series, financing characteristics, II